Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
And that sneaky bitch thought we wouldnt recognize her
#AcuteDecompensation #ACLF #Inflammation #LiverDisease #GENFIT #G1090N *G1090N is an investigational drug candidate.* European Foundation for the Study of Chronic Liver Failure (EF CLIF), European Liver Patients' Association - ELPA Global Liver Institute American Liver Foundation To view or add a comment, sign in Following recent Phase 1 data that provided a solid foundation for advancing G1090N into Phase 2 proof-of-concept studies across the ACLF continuum, explore our latest scientific poster presented at AASLD 2025 to learn more about its active metabolite and earlier body of evidence
You may request a free 15-minute consultation with Dr
It is produced by modifying the Cterminus of the MTII scaffold replacing the terminal amide with a hydroxyl group yielding a related cyclic peptide with a distinct receptorselectivity profile while retaining the lactambridged, enzymatically stable architecture of its parent compound
US$ 25.10
US$ 23.56
US$ 28.70
US$ 24.15
US$ 29.34
US$ 25.36
US$ 26.58
US$ 20.40
US$ 26.49
US$ 20.70
US$ 26.00
US$ 21.98
